Aurobindo Pharma receives final approval for Cyclobenzaprine Hydrochlorid Tablets
Aurobindo Pharma Ltd is pleased to announce that the Company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cyclobenzaprine Hydrochloride Tablets USP 5mg and 10mg.
Cyclobenzaprine Hydrochloride Tablets is the generic version of MCNEIL-PPC's Flexeril tablets 5mg and 10mg and is indicated as an adjunct for relief of muscle spasm.
This is Aurobindo's 79th ANDA approval from the USFDA.
The Stock was trading at Rs.192.30, down by Rs.18.65 or 8.84%. The stock hit an intraday high of Rs.203.20 and low of Rs.182.
The total traded quantity was 45326 compared to 2 week average of 34086.
